Valneva (NASDAQ:VALN) Shares Gap Down – Should You Sell?

Valneva SE Sponsored ADR (NASDAQ:VALN) shares gapped down prior to trading on Thursday. The stock had previously closed at $5.87, but opened at $5.61. Valneva shares last traded at $5.6550, with a volume of 6,142 shares trading hands.

Analysts Set New Price Targets

VALN has been the subject of a number of recent analyst reports. TD Cowen started coverage on Valneva in a report on Tuesday, August 11th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a research note on Monday, September 14th. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Valneva has an average rating of “Reduce” and an average target price of $9.30.

Valneva Stock Performance

The company has a quick ratio of 1.69, a current ratio of 2.16 and a debt-to-equity ratio of 2.04. The stock has a fifty day moving average price of $6.27 and a two-hundred day moving average price of $5.87. The company has a market capitalization of $538.03 million, a price-to-earnings ratio of -2.69 and a beta of 1.53.

Valneva (NASDAQ:VALN) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.21). The firm had revenue of $39.37 million for the quarter, compared to analysts’ expectations of $44.17 million. Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%. As a group, analysts forecast that Valneva SE Sponsored ADR will post -1.27 EPS for the current fiscal year.

Valneva Company Profile

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company develops, manufactures and commercializes vaccines intended to address infectious diseases with significant unmet medical needs, including travel-related illnesses, endemic diseases and emerging public-health threats.

Valneva’s marketed products include IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain types of traveler’s diarrhea.